Data collection in Lutetium Treated Prostate cancer: Recording of Progression and Tumor Characteristics

• Conditions: metastatic castration-resistant prostate cancer; Prostate cancer; 10038597

• Registration Number: NL-OMON56531
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 150

Inclusion Criteria

- Participants should be at least 18 years old.
- Participants should be able to understand the written information and be able
to provide informed consent.
- Participants are planned to start treatment with Lu-PSMA as a part of regular
clinical care.

Exclusion Criteria

None Applicable

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The present study is observational in nature. The study tracks overall survival<br /><br>as endpoint to assess the efficacy of treatment.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Progression free survival on the basis of clinical data, radiological imaging<br /><br>as well as PSA.<br /><br>Heterogeneity of PSMA-positivity in circulating tumor cells (CTC) prior to<br /><br>treatment with Lutetium-PSMA.<br /><br>Association between ctDNA in blood and other biomarkers with treatment outcomes<br /><br>of Lutetium-PSMA treatment.<br /><br>Association between PSMA-PET and therapy scans with treatment outcomes of<br /><br>Lutetium-PSMA treatment.</p><br>